TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 168 filers reported holding TURNING POINT THERAPEUTICS I in Q3 2020. The put-call ratio across all filers is 1.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $25,821,000 | +173.8% | 343,133 | -2.3% | 0.01% | +200.0% |
| Q1 2022 | $9,430,000 | -42.7% | 351,194 | +1.9% | 0.00% | -40.0% |
| Q4 2021 | $16,447,000 | -26.5% | 344,795 | +2.4% | 0.01% | -28.6% |
| Q3 2021 | $22,362,000 | -10.3% | 336,610 | +5.3% | 0.01% | -12.5% |
| Q2 2021 | $24,943,000 | -10.1% | 319,694 | +9.0% | 0.01% | -20.0% |
| Q1 2021 | $27,737,000 | -15.5% | 293,227 | +8.9% | 0.01% | -23.1% |
| Q4 2020 | $32,808,000 | +59.9% | 269,243 | +14.7% | 0.01% | +44.4% |
| Q3 2020 | $20,515,000 | +112.8% | 234,822 | +57.3% | 0.01% | +80.0% |
| Q2 2020 | $9,642,000 | +83.1% | 149,268 | +26.6% | 0.01% | +66.7% |
| Q1 2020 | $5,265,000 | -27.3% | 117,890 | +1.4% | 0.00% | -25.0% |
| Q4 2019 | $7,243,000 | +170.2% | 116,265 | +63.1% | 0.00% | +100.0% |
| Q3 2019 | $2,681,000 | +29.4% | 71,303 | +40.1% | 0.00% | +100.0% |
| Q2 2019 | $2,072,000 | – | 50,906 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 2,392,297 | $291,501,000 | 6.94% |
| Burrage Capital Management LLC | 72,484 | $8,832,000 | 6.73% |
| MPM BioImpact LLC | 617,372 | $75,226,000 | 6.50% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 113,541 | $13,816,000 | 3.77% |
| Orbimed Advisors | 2,745,327 | $334,518,000 | 2.93% |
| SECTORAL ASSET MANAGEMENT INC | 257,379 | $31,362,000 | 2.21% |
| Parkman Healthcare Partners LLC | 59,377 | $7,235,000 | 1.85% |
| Nicholas Investment Partners, LP | 183,676 | $22,381,000 | 1.73% |
| EMERALD ADVISERS, LLC | 357,038 | $43,505,000 | 1.44% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 336,173 | $40,963,000 | 1.42% |